1.62
0.04 (2.53%)
| Penutupan Terdahulu | 1.58 |
| Buka | 1.55 |
| Jumlah Dagangan | 1,462,937 |
| Purata Dagangan (3B) | 2,915,883 |
| Modal Pasaran | 115,364,008 |
| Harga / Jualan (P/S) | 17.53 |
| Harga / Buku (P/B) | 2.60 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Operasi (TTM) | -9,653.85% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 24.34% |
| Nisbah Semasa (MRQ) | 4.93 |
| Aliran Tunai Operasi (OCF TTM) | -49.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.61 M |
| Pulangan Atas Aset (ROA TTM) | -31.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ovid Therapeutics Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 16.31% |
| % Dimiliki oleh Institusi | 55.97% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (Leerink Partners, 208.64%) | Beli |
| Median | 3.50 (116.05%) | |
| Rendah | 2.00 (HC Wainwright & Co., 23.46%) | Beli |
| Purata | 3.50 (116.05%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.40 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Nov 2025 | 2.00 (23.46%) | Beli | 1.49 |
| Leerink Partners | 17 Nov 2025 | 5.00 (208.64%) | Beli | 1.30 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |